100 项与 S. aureus combined vaccine(University of Chicago) 相关的临床结果
100 项与 S. aureus combined vaccine(University of Chicago) 相关的专利（医药）
项与 S. aureus combined vaccine(University of Chicago) 相关的文献（医药）
2023-10-06·Avian pathology : journal of the W.V.P.A
A Salmonella Pullorum outbreak with neurological signs in adult layers and outbreak investigation using Whole Genome Sequencing.
作者: Robert Jan Molenaar ; Remco Dijkman ; Christiaan Ter Veen ; Annet Heuvelink ; Fiona van Kaam ; Marieke Augustijn ; Anneke Feberwee
This report describes a Salmonella enterica subspecies enterica serovar Gallinarum biovar Pullorum (SP) outbreak in a Dutch laying flock of 65 weeks of age (W) showing increased mortality, decreased egg production and neurological signs. The flock was vaccinated three times with a live S. Enteritis and S. Typhimurium vaccine in the rearing period. At 71 W, as mortality peaked, a live SG 9R vaccine was applied. At 76 W mortality decreased and egg production stabilized but did not return to a normal level.Post-mortem, histological, bacteriological and serological examinations were frequently performed. Gross findings in diseased and dead birds were characterized by hepato- and splenomegaly and oophoritis. SP was frequently isolated from liver, spleen, ovary and bone marrow and isolation rate did not vary significantly between the different organs. Histological examination and immunostaining of birds with neurological signs showed cerebral granulomas in the presence of Salmonella. Previous Salmonella vaccinations did not hamper the detection of specific SP antibodies (positive at serum dilution ≥ 1:8) using a commercial rapid plate agglutination test. At 85 W 40 clinically healthy birds were investigated and three had ovarian lesions, explaining egg production not returning to normal. These birds had antibodies against SP, indicating contact with the bacterium, but carrier status could not be confirmed by culture. phylogenetic analysis showed SP isolates within this outbreak to be clonal and differing from SP isolates from previous outbreaks.Research highlights: Cerebral granulomas associated with nervous signs in Salmonella Pullorum outbreakBone marrow also a recommended tissue for isolation of Salmonella PullorumRapid plate agglutination test detects Pullorum antibodies in vaccinated flockPhylogenetic analysis showed clonality of isolates within the outbreak.
2023-04-01·Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
A highly-safe live auxotrophic vaccine protecting against disease caused by non-typhoidal Salmonella Typhimurium in mice
作者: Garcia, Patricia ; Moscoso, Miriam ; Fuentes-Valverde, Victor ; Rodicio, M. Rosario ; Herrera-Leon, Silvia ; Bou, German
Salmonella enterica serovar Typhimurium (S. Typhimurium) has become an important intestinal pathogen worldwide and is responsible for lethal invasive infections in populations at risk. There is at present an unmet need for preventive vaccines.
IRTA GN-3728 genome was sequenced by Illumina and d-glutamate and d-glutamate/d-alanine knockout-auxotrophs were constructed. They were characterized using electron microscopy, growth/viability curves, reversion analysis, and motility/agglutination assays. Their potential as vaccine candidates were explored using two BALB/c mouse models for Salmonella infections: a systemic and an intestinal inflammation. Clinical signs/body weight and survival were monitored, mucosal lactoferrin and specific/cross-reactive IgA/IgG were quantified by enzyme-linked-immunosorbent assays and bacterial shedding/burden in fecal/tissues were evaluated.
The d-glutamate auxotroph, IRTA ΔmurI, is highly attenuated, immunogenic and fully protective against systemic infection. The IRTA ΔmurI Δalr ΔdadX double auxotroph, constructed to reinforce vaccine safety, showed a higher level of attenuation and was 100% effective against systemic disease. In the intestinal model, it proved to be safe, yielding a low-degree of mucosal inflammation, short-term shedding and undetectable invasiveness in the long-term, while eliciting cross-reactive fecal IgA/serum IgG against clinically relevant multidrug-resistant (MDR) S. Typhimurium strains. It also conferred protection against homologous oral challenge, and protected mice from local and extra-intestinal dissemination caused by one MDR strain responsible for an international outbreak of highly severe human infections. Additionally, oral vaccination promoted extended survival after lethal heterologous infection.
This study yielded a very safe S. Typhimurium vaccine candidate that could be further refined for mucosal application against disease in humans.
Oral Vaccination with Engineered Probiotic Limosilactobacillus reuteri Has Protective Effects against Localized and Systemic Staphylococcus aureus Infection.
作者: Na Pan ; Yang Liu ; Haochi Zhang ; Ying Xu ; Xuemei Bao ; Shouxin Sheng ; Yanchen Liang ; Bohui Liu ; Yueqing Lyu ; Haotian Li ; Fangfei Ma ; Haiting Pan ; Xiao Wang
Staphylococcus aureus is a Gram-positive bacterium responsible for most hospital-acquired (nosocomial) and community-acquired infections worldwide. The only therapeutic strategy against S. aureus-induced infections, to date, is antibiotic treatment. A protective vaccine is urgently needed in view of the emergence of antibiotic-resistant strains associated with high-mortality cases; however, no such vaccine is currently available. In our previous work, the feasibility of implementing a Lactobacillus delivery system for development of S. aureus oral vaccine was first discussed. Here, we describe systematic screening and evaluation of protective effects of engineered Lactobacillus against S. aureus infection in terms of different delivery vehicle strains and S. aureus antigens and in localized and systemic infection models. Limosilactobacillus reuteri WXD171 was selected as the delivery vehicle strain based on its tolerance of the gastrointestinal environment, adhesion ability, and antimicrobial activities in vitro and in vivo. We designed, constructed, and evaluated engineered L. reuteri strains expressing various S. aureus antigens. Among these, engineered L. reuteri WXD171-IsdB displayed effective protection against S. aureus-induced localized infection (pneumonia and skin infection) and, furthermore, a substantial survival benefit in systemic infection (sepsis). WXD171-IsdB induced mucosal responses in gut-associated lymphoid tissues, as evidenced by increased production of secretory IgA and interleukin 17A (IL-17A) and proliferation of lymphocytes derived from Peyer's patches. The probiotic L. reuteri-based oral vaccine appears to have strong potential as a prophylactic agent against S. aureus infections. Our findings regarding utilization of Lactobacillus delivery system in S. aureus vaccine development support the usefulness of this live vaccination strategy and its potential application in next-generation vaccine development. IMPORTANCE We systematically screened and evaluated protective effects of engineered Lactobacillus against S. aureus infection in terms of differing delivery vehicle strains and S. aureus antigens and in localized and systemic infection models. Engineered L. reuteri was developed and showed strong protective effects against both types of S. aureus-induced infection. Our findings regarding the utilization of a Lactobacillus delivery system in S. aureus vaccine development support the usefulness of this live vaccination strategy and its potential application in next-generation vaccine development.
100 项与 S. aureus combined vaccine(University of Chicago) 相关的药物交易